ArticleJournal of arrhythmia2026
Electrophysiological Substrate and Ablation Outcomes in Atrial Fibrillation With Hypertrophic Cardiomyopathy: A Propensity-Matched Multicenter Study.
Article in Journal of arrhythmia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atrial fibrillation (AF) is the most common sustained arrhythmia in hypertrophic cardiomyopathy (HCM), yet the intracardiac electrophysiological substrate underlying recurrence following catheter ablation remains poorly characterized. We compared the atrial substrate and ablation outcomes between HCM-AF patients and propensity-score-matched lone AF controls. Methods: This multicenter retrospective study was conducted across three tertiary centers in Pakistan (2015-2023). Of 841 screened patients, 143 HCM-AF patients were matched 1:1 with 143 lone AF controls on 14 covariates. Left atrial (LA) electroanatomic voltage mapping, intracardiac electrophysiological variables, and AF inducibility were compared. Primary endpoints were LA low-voltage area (LVA) burden, AF inducibility, and 12-month freedom from recurrence post-ablation. Results: HCM-AF patients had greater LVA burden (29.7% ± 17.4% vs. 11.8% ± 9.7%, Conclusion: HCM-AF is associated with a more arrhythmogenic atrial substrate and inferior ablation outcomes compared with lone AF. LVA burden is the strongest predictor of recurrence. EP substrate phenotyping may enable meaningful risk stratification in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.